Text Size

A Study of Quantitative Assessments of Angle Width in Chinese Patients With Open-angle Glaucoma and/or Ocular Hypertension

This study is currently recruiting participants.
Verified January 2013 by Allergan
Sponsor:
Information provided by (Responsible Party):
Allergan
ClinicalTrials.gov Identifier:
NCT01781962
First received: January 30, 2013
Last updated: January 31, 2013
Last verified: January 2013
History of Changes
  Purpose

This study will assess angle width in Chinese patients with Open-angle Glaucoma and/or Ocular Hypertension.


Condition Intervention
Open-angle Glaucoma
Ocular Hypertension
 Other: No Treatment

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Allergan:

Primary Outcome Measures:
  • Anterior Angle Width as Measured by Anterior Segment Optical Coherence Tomography [ Time Frame: Day 1 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Anterior Angle Width as Measured by Gonioscopic Lens with Shaffer Grading [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
  • Anterior Angle Width as Measured by Gonioscopic Lens with Step Grading [ Time Frame: Day 1 ] [ Designated as safety issue: No ]

Estimated Enrollment: 250
Study Start Date: January 2013
Estimated Study Completion Date: September 2013
Estimated Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
OAG and/or OHT patients
Open-Angle Glaucoma (OAG) and/or Ocular Hypertension (OHT) patients.
 Other: No Treatment
No Treatment was given in this study.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Chinese patients with Open-angle Glaucoma and/or Ocular Hypertension

Criteria

Inclusion Criteria:

  • Of Chinese descent
  • Open-angle Glaucoma or Ocular Hypertension in each eye

Exclusion Criteria:

  • History of a narrow-angle or angle closure glaucoma
  • Angle abnormalities in either eye
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01781962

Contacts
Contact: Allergan Inc. clinicaltrials@allergan.com

Locations
China
Recruiting
Beijing, China
Sponsors and Collaborators
Allergan
Investigators
Study Director: Medical Director Allergan
  More Information

Additional Information:
More Information  This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party: Allergan
ClinicalTrials.gov Identifier: NCT01781962     History of Changes
Other Study ID Numbers: 192024-077
Study First Received: January 30, 2013
Last Updated: January 31, 2013
Health Authority: China: Ethics Committee

Additional relevant MeSH terms:
Glaucoma
Glaucoma, Open-Angle
Hypertension
Ocular Hypertension
 Eye Diseases
Vascular Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on May 23, 2013